04 MAR 2005

From the INTERNATIONAL SEARCHING AUTHORITY

| P.C ONE FINANCIAL CENTER BOSTON, MA 02111 Applicant's or agent's file reference 17811-017CIP International application No. | NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION (PCT Rule 44.1) Date of Mailing (day/month/year) FOR FURTHER ACTION See paragraphs 1 and 4 below International filing date |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PCT/US03/27888 | (day/month/year) 05 September 2003 (05.09.2003) |
| Applicant ISOTIS SA | |
| 1. The applies hereby notified that the nation of as idments and statement. Article 19 | the report has been established by a samitted herewith. |
| The applicant is entitled, if he so wishes Tramend the c | laims of the international ap _{resc} ation (see Rule 46): |
| When? The time limit for filing such amendments international search report. | is normally two months from the date of transmittal of the |
| Where? Directly to the International Bureau of WIP 1211 Geneva 20, Switzerland, Facsimile No. | · · · |
| For more detailed instructions, see the notes on the | accompanying sheet. |
| 2. The applicant is hereby notified that no international sear Article 17(2)(a) to that effect is transmitted herewith. | rch report will be established and that the declaration under |
| 3. With regard to the protest against payment of (an) addi | itional fee(s) under Rule 40.2, the applicant is notified that: |
| | een transmitted to the International Bureau together with the protest and the decision thereon to the designated Offices. |
| no decision has been made yet on the protest; the a | pplicant will be notified as soon as a decision is made. |
| 4. Reminders | |
| applicant wishes to avoid or postpone publication, a notice of w | onal application will be published by the International Bureau. If the ithdrawal of the international application, or of the priority claim, must 1 and 90 bis.3, respectively, before the completion of the technical |
| examination must be filed if the applicant wishes to postpone the | at of some designated Offices, a demand for international preliminary the entry into the national phase until 30 months from the priority date thin 20 months from the priority date, perform the prescribed acts for |
| In respect of other designated Offices, the time limit of 30 months | ths (or later) will apply even if no demand is filed within 19 months. |
| See the Annex to Form PCT/IB/301 and, for details about the a Volume II, National Chapters and the WI | applicable time limits, Office by Office, see the PCT Applicant's Guide, |
| Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230 DEC 0 8 2 MINTZ LEVIN, E PATENT DOCKE | |

Form PCT/ISA/220 (April 2002)

(See notes on accompanying sheet)

PATENT COOPERATION TREAT

From the INTERNATIONAL SEARCHING AUTHORITY

| BOSTON, MA 02111 Docket Cross Off Previously Entered No Docketing Day | THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION (PCT Rule 44.1) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ☐ Order Coples ☐ Annuities | Date of Mailing (day/month/year) 04 DEC 2003 |
| Applicant's or agent's file reference 17811-017CIP | FOR FURTHER ACTION See paragraphs 1 and 4 below |
| International application No. PCT/US03/27888 | International filing date (day/month/year) 05 September 2003 (05.09.2003) |
| Applicant ISOTIS SA | |
| international search report. Where? Directly to the International Bureau of WIPO, | ms of the international application (see Rule 46): normally two months from the date of transmittal of the 34, chemin des Colombettes |
| 1211 Geneva 20, Switzerland, Facsimile No.: For more detailed instructions, see the notes on the acc | |
| The applicant is hereby notified that no international search Article 17(2)(a) to that effect is transmitted herewith. With regard to the protest against payment of (an) addition the protest together with the decision thereon has been | report will be established and that the declaration under and fee(s) under Rule 40.2, the applicant is notified that: I transmitted to the International Bureau together with the stotest and the decision thereon to the designated Offices. |
| applicant wishes to avoid or postpone publication, a notice of with reach the International Bureau as provided in Rules 90 bis.1 a preparations for international publication. Within 19 months from the priority date, but only in respect of examination must be filed if the applicant wishes to postpone the (in some Offices even later); otherwise the applicant must, within entry into the national phase before those designated Offices. In respect of other designated Offices, the time limit of 30 months | al application will be published by the International Bureau. If the drawal of the international application, or of the priority claim, must and 90 bis.3, respectively, before the completion of the technical of some designated Offices, a demand for international preliminary entry into the national phase until 30 months from the priority date un 20 months from the priority date, perform the prescribed acts for (or later) will apply even if no demand is filed within 19 months. |
| Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230 | Authorized officer Christopher Nichols, Ph.D. Telephone No. 703-308-0196 |
| Form PCT/ISA/220 (April 2002) | |

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file refere | FOR FURTHE ACTION | | cation of Transmittal of International Search Report T/ISA/220) as well as, where applicable, item 5 |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| International application No. PCT/US03/27888 | International filing date 05 September 2003 (05. | | (Earliest) Priority Date (day/month/year) 06 September 2002 (06.09.2002) |
| Applicant ISOTIS SA | | | |
| applicant according to Article 1 | 18. A copy is being transmitted t | to the International | Authority and is transmitted to the Bureau. |
| This international search report It is also account | consists of a total of sheet ompanied by a copy of each prior | | d in this report. |
| language in which it the international se Authority (Rule 23 b. With regard to any n | was filed, unless otherwise indicate arch was carried out on the basis of 1.1(b)). ucleotide and/or amino acid sequ | ed under this item. of a translation of th uence disclosed in the | e basis of the international application in the se international application furnished to this se international application, the international |
| contained in the in | at on the basis of the sequence listi ternational application in written for the international application in con- | orm. mputer readable for | m. |
| | ently to this Authority in written for ently to this Authority in computer | | |
| | the subsequently furnished written cation as filed has been furnished. | sequence listing doe | es not go beyond the disclosure in the |
| the statement that the been furnished. | he information recorded in compu | ter readable form is | identical to the written sequence listing has |
| 2. Certain claims we | ere found unsearchable (See Box) | I). | |
| 3. Unity of invention 4. With regard to the title, | is lacking (See Box II). | | |
| the text is approved | d as submitted by the applicant. | | |
| the text has been es | stablished by this Authority to read | i as follows: | |
| 5. With regard to the abstract | | | |
| the text is approved | d as submitted by the applicant. | | |
| | | | y as it appears in Box III. The applicant ch report, submit comments to this |
| 6. The figure of the drawings | to be published with the abstract i | s Figure No. | |
| as suggested by the | applicant. | | None of the figures |
| because the applica | unt failed to suggest a figure. | | |
| because this figure | better characterizes the invention. | | |

Form PCT/ISA/210 (first sheet) (July 1998)





| | • | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| · | | |
| | | |
| | · | |
| | | |
| | | |
| · | | |
| | | |
| | | |
| | | |
| Continuation of B. FIELDS SEARCHED Item 3: WEST (USPT, PGPUBS, JPO, EPO, DERWENT); NCBI (PUBMED); STN (B | NOSCIENCE) | |
| | allogeneic, epithelial, blood, mitomycin C, X-ray, | |
| scaffold wound dressing Tantigen FRV HTI V-1 FRNA2 glycerol c-myc | c-kun mye n-mye | |
| WEST (USPT, PGPUBS, JPO, EPO, DERWENT); NCBI (PUBMED); STN (B fibroblast, keratinocyte, differentiated, differentiation, fibrin, collagen, matrix, scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. mye, n-mye | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | e-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |
| scaffold, wound dressing, T antigen, EBV, HTLV-1, EBNA2, glycerol, c-myc, | c-kun. myc, n-myc | |

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/27888

| A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 35/00, 48/00; C07K 5/00, 14/00; C12N US CL : 424/93.1; 435/325; 514/44; 530/300, 350, 39 | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|--------------------------|
| According to International Patent Classification (IPC) or to both | | |
| B. FIELDS SEARCHED | | |
| Minimum documentation searched (classification system followed U.S.: 424/93.1; 435/325; 514/44; 530/300, 350, 399 | l by classification symbols) | |
| Documentation searched other than minimum documentation to the | ne extent that such documents are included | l in the fields searched |
| Electronic data base consulted during the international search (na Please See Continuation Sheet | me of data base and, where practicable, so | earch terms used) |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | _ | |
| Category * Citation of document, with indication, where a | ppropriate, of the relevant passages | Relevant to claim No. |
| X US 5,891,558 A (BELL et al.) 06 April 1999 (06.0 |)4.1999), Cols. 4-19. | 1-91 |
| X US 5,855,617 A (ORTON) 05 January 1999 (05.01 | 1.1999), Cols. 4-6. | · 1-91 |
| X US 5,863,296 A (ORTON) 26 January 1999 (26.01 | .1999), Cols. 4-7. | 1-91 |
| X,P US 2003/0064927 A1 (GESTRELIUS et al.) 03 Ap | ril 2003 (03.04.2003), Examples 1-9. | 1-91 |
| X,P US 2003/0166274 A1 (HEWITT et al.) 04 Septem | ber 2003 (04.09.2003), Examples I-IX. | 1-91 |
| X COOPER, M.L. et al. Use of a compsite skin graft keratinocytes and fibroblasts and a collagen-GAG r on athymic mice. Surgery. February 1991, Vol. 10 Figures 1 and 4, Table I. | natrix to cover full-thickness wounds | 1-91 |
| Further documents are listed in the continuation of Box C. | See patent family annex. | |
| Special categories of cited documents: | "T" later document published after the inter | |
| "A" document defining the general state of the art which is not considered to be of particular relevance | date and not in conflict with the applica principle or theory underlying the inver | |
| "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the c considered novel or cannot be considered when the document is taken alone | |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the considered to involve an inventive step combined with one or more other such | when the document is |
| "O" document referring to an oral disclosure, use, exhibition or other means | being obvious to a person skilled in the | art |
| "P" document published prior to the international filing date but later than the priority date claimed | "&" document member of the same patent for | amily |
| Date of the actual completion of the international search | Date of mailing of the international search | C 2003 |
| 31 October 2003 (31.10.2003) Name and mailing address of the ISA/US | Authorized officer | () |
| Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 | Christopher Nichols, Ph.D. | 5 |
| Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230 | Teléphone No. 703-308-0196 | / |

Form PCT/ISA/210 (second sheet) (July 1998)

PCT/US03/27888

INTERNATIONAL SEARCH REPORT

| ategory * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| X | LANGDON, R.C. et al. Reconstitution of Structure and Cell Function in Human Skin Grafts Derived from Cryopreserved Allogeneic Dermis and Autologous Cultured Keratinocytes. J Invest Dermatol. November 1988, Vol. 91, No. 5, pages 478-485, especially Figures 1-4. | 1-91 |
| x J | SUGIHARA, H. et al. Effects of fat cells on keratinocytes and fibroblasts in a reconstructed rat skin model using collagen gel matrix culture. British Journal of Dermatology. 2001, Vol. 144, pages 244-253, especially Figures 1 and 2. | 1-91 |
| x V | KOLODKA, T.M. et al. Evidence for keratinocyte stem cells in vitro: Long term engraftment and persistene of transgene expression form retrovirus-transfected keratinocytes. Proc. Natl. Acad. Sci., USA. April 1998, Vol. 95, pages 4356-4361, especially Table 1 and 2. | 1-91 |
| x / | BADIAVAS, E. et al. Retrovirally mediated gene transfer in a skin equivalent model of chronic wounds. Journal of Dermatological Science. 1996, Vol. 13, pages 56-62, especially Figure 3. | 1-91 |
| x 🗸 | / MARUGUCHI, T.et al. A new skin equivalent: Keratinocytes proliferated and differentiated on collagen sponge containing fibroblasts. Plast. Reconstr. Surg. March 1994, Vol. 93, No. 3, pages 537-546, especially Figures 1-4. | 1-91 |
| A,P | US 2002/0169105 A1 (GESTRELIUS et al.) 14 November 2002 (14.11.2002), entire document. | 1-91 |
| Αυ | US 2002/0031500 A1 (MACLAUGHLIN et al.) 14 March 2002 (14.03.2002), entire document. | 1-91 |
| A 🗸 | KUROYANAGI, Y. et al. A cultured skin substitute composed of fibroblasts and keratinocytes with a collagen matrix: Preliminary results of clinical trials. Ann Plast Surg. October 1993, Vol. 31, No. 4, pages 340-351, entire document. | 1-91 |
| A 🤝 | DEL RIO, M. et al. A preclinical model for the analysis of genetically modified human skin in vivo. Human Gene Therapy. 20 May 2002, Vol. 13, No. 8, pages 959-968, entire document. | 1-91 |
| A V | CURRIE, L.J. et al. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: A Review. Plast Reconstr Surg. November 2001, Vol. 108, No. 6, pages 1713-1726, entire document. | 1-91 |
| ; | · | |
| | | |
| | | |
| | | |
| | | |